<DOC>
	<DOCNO>NCT00016237</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill tumor cell . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Interleukin-2 combine monoclonal antibody may effective treatment kidney , bladder , lung cancer . PURPOSE : Phase I trial study effectiveness interleukin-2 combine monoclonal antibody treat patient kidney , bladder , lung cancer respond previous treatment .</brief_summary>
	<brief_title>Interleukin-2 Combined With Monoclonal Antibody Therapy Treating Patients With Kidney , Bladder , Lung Cancer That Has Not Responded Previous Treatment</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose KSA-interleukin-2 patient refractory epithelial carcinoma . II . Characterize pharmacokinetics drug patient . III . Assess overall toxicity safety drug patient . IV . Determine rate objective response patient treated drug . OUTLINE : This dose-escalation , multicenter study . Patients receive KSA-interleukin-2 ( KSA-IL-2 ) IV 1 hour day 1-5 . Treatment repeat every 21 day maximum 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos KSA-IL-2 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 33 % patient experience dose-limiting toxicity . Patients follow 30 day . PROJECTED ACCRUAL : Approximately 12-24 patient accrue study within 6-12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm epithelial carcinoma 1 following : Renal cell carcinoma Bladder carcinoma Lung carcinoma Refractory disease anticipate benefit conventional treatment No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL WBC least 3,500/mm3 OR Granulocyte count least 2,000/mm3 Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) AST ALT great 3 time ULN Renal : Creatinine le 2 time ULN Cardiovascular : Normal EKG No prior myocardial infarction No arteriovenous block great I , complete hemiblock , hypertrophy , relevant arrhythmia No uncontrolled hypertension ( diastolic least 100 mmHg ) hypotension ( systolic great 90 mmHg ) No prior episodes syncope No prior cardiac disease significant risk factor coronary artery disease , unless evidence myocardial ischemia exercise thallium scan exam ( e.g. , exercise EKG dobutamine stress echocardiography ) evidence significantly impaired leave ventricular function echocardiographic exam Normal thallium scan patient least 65 year old Pulmonary : Normal chest xray No pulmonary congestion , pleural effusion , pulmonary fibrosis , significant emphysema Other : No concurrent infection No clinical evidence immunosuppression No known hypersensitivity study drug , interleukin2 , Tween80 , human immunoglobin No condition would preclude study No Addison 's disease No Crohn 's disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study Thyroidsensitizing hormone great 4.7 mU/L PRIOR CONCURRENT THERAPY : Biologic therapy : At least 30 day since prior biologic therapy No concurrent immunotherapy Chemotherapy : At least 30 day since prior chemotherapy ( 6 week since mitomycin nitrosoureas ) No concurrent chemotherapy Endocrine therapy : At least 30 day since prior endocrine therapy No concurrent systemic corticosteroid therapy Radiotherapy : No prior radiotherapy least 25 % bone marrow At least 30 day since prior radiotherapy At least 3 month since prior radioisotope therapy ( e.g. , strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium ) No concurrent radiotherapy Surgery : At least 3 week since prior major surgery No prior organ transplantation Other : At least 30 day since prior investigational drug No prior therapy would preclude study No concurrent investigational drug No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>squamous cell carcinoma bladder</keyword>
</DOC>